Literature DB >> 9618745

Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach.

E Bezard1, C E Gross.   

Abstract

This paper provides an overview of the compensatory mechanisms which come into action during experimental and human parkinsonism. The intrinsic properties of the dopaminergic neurones of the substantia nigra pars compacta (SNc) which degenerate during Parkinson's disease are described in detail. It is generally considered that the nigrostriatal pathway is principally responsible for the compensatory preservation of dopaminergic function. It is also becoming clear that the morphological characteristics of dopaminergic neurones and the dual character, synaptic and asynaptic, of striatal dopaminergic innervation engender two modes of transmission, wiring and volume, and that both these modes play a role in the preservation of dopaminergic function. The plasticity of the dopamine neurones, extrinsic or intrinsic to the striatum, can thus be regarded as another compensatory mechanism. Recent anatomical and electrophysiological studies have shown that the SNc receives both glutamatergic and cholinergic inputs. The dynamic role this innervation plays in compensatory mechanisms in the course of the disease is explained and discussed. Recent developments in the field of compensatory mechanisms speak for the urgence to develop a valid chronic model of Parkinson's disease, integrating all the clinical features, even resting tremor, and illustrating the gradual evolution of nigral degeneration observed in human Parkinson's disease. Only a dynamic approach to the physiopathological study of compensatory mechanisms in the basal ganglia will be capable of elucidating these complex questions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618745     DOI: 10.1016/s0301-0082(98)00006-9

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  49 in total

1.  A new mouse model to study compensatory mechanisms that support normal motor function in Parkinson's disease.

Authors:  Xiang Bai; Stacy A Hussong
Journal:  J Biochem Pharmacol Res       Date:  2014-06

2.  Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Vsevolod V Gurevich; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Neurochem       Date:  2007-11-07       Impact factor: 5.372

3.  "Provocation test" as a novel approach to early diagnosis of Parkinson's disease.

Authors:  G R Khakimova; E A Degtyareva; E A Kozina; V G Kucheryanu; M V Ugrumov
Journal:  Dokl Biol Sci       Date:  2015-03-13

4.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

5.  Time course of degeneration of dopaminergic neurons and respective compensatory processes in the nigrostriatal system in mice.

Authors:  A A Kolacheva; E A Kozina; E V Volina; M V Ugryumov
Journal:  Dokl Biol Sci       Date:  2014-07-02

6.  Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro.

Authors:  Joshua L Fuqua; Ofelia M Littrell; Martin Lundblad; Jadwiga Turchan-Cholewo; Lina G Abdelmoti; Emilia Galperin; Luke H Bradley; Wayne A Cass; Don M Gash; Greg A Gerhardt
Journal:  Peptides       Date:  2014-01-07       Impact factor: 3.750

7.  Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  F L'Episcopo; C Tirolo; N Testa; S Caniglia; M C Morale; C Cossetti; P D'Adamo; E Zardini; L Andreoni; A E C Ihekwaba; P A Serra; D Franciotta; G Martino; S Pluchino; B Marchetti
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

8.  5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch; Twum A Ansah
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

9.  MPTP-induced executive dysfunction is associated with altered prefrontal serotonergic function.

Authors:  Panchanan Maiti; Laura C Gregg; Michael P McDonald
Journal:  Behav Brain Res       Date:  2015-09-21       Impact factor: 3.332

10.  Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate.

Authors:  Quentin Barraud; Ibrahim Obeid; Incarnation Aubert; Gregory Barrière; Hugues Contamin; Steve McGuire; Paula Ravenscroft; Gregory Porras; François Tison; Erwan Bezard; Imad Ghorayeb
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.